Skip to main content

Table 2 Change scores and standardized response means for fatigue measures

From: Comparative responsiveness and minimally important difference of Fatigue Symptom Inventory (FSI) scales and the FSI-3 in trials with cancer survivors

Fatigue measure Global category

MBSR trials (N = 106, Worse n = 11, Same n = 34, Better n = 59)

BEAT Cancer trial (N = 222, Worse n = 37, Same n = 89, Better n = 89)

Change score (SD)

p value

SRM

(95% CIs)

Change score (SD)

p value

SRM

(95% CIs)

FSI Total

 Worse

− 0.70 (1.57)

0.631

− 0.45

(− 1.16, 0.31)

1.22 (1.37)

 < 0.001

0.89

(0.53, 1.20)

 Same

− 0.98 (1.70)

− 0.58

(− 0.83, − 0.28)

0.05 (1.15)

0.05

(− 0.16, 0.26)

 Better

− 1.96 (1.74)

0.010

− 1.13

(− 1.47, − 0.81)

− 1.19 (1.32)

 < 0.001

− 0.90

(− 1.10, − 0.70)

FSI Severity

 Worse

− 0.55 (1.75)

0.759

− 0.31

(− 1.10, 0.37)

1.22 (1.29)

 < 0.001

0.95

(0.63, 1.28)

 Same

− 0.75 (1.95)

− 0.38

(− 0.70, − 0.08)

0.12 (1.37)

0.09

(− 0.13, 0.29)

 Better

− 1.65 (1.88)

0.031

− 0.88

(− 1.18, − 0.57)

− 1.27 (1.62)

 < 0.001

− 0.78

(− 0.99, − 0.57)

FSI Interference

 Worse

− 0.87 (1.85)

0.769

− 0.47

(− 1.28, 0.28)

1.19 (1.74)

 < 0.001

0.69

(0.37, 0.99)

 Same

− 1.06 (1.89)

− 0.56

(− 0.81, − 0.26)

0.03 (1.46)

–− 

0.02

(− 0.19, 0.23)

 Better

− 2.16 (2.01)

0.011

− 1.08

(− 1.40, − 0.74)

− 1.11 (1.42)

 < 0.001

− 0.78

(− 0.99, − 0.57)

FSI-3

 Worse

− 0.45 (1.92)

0.332

− 0.24

(− 0.97, 0.51)

1.41 (1.66)

 < 0.001

0.86

(0.47, 1.20)

 Same

− 1.20 (2.25)

− 0.53

(− 0.82, − 0.21)

0.18 (1.34)

0.13

(− 0.08, 0.33)

 Better

− 2.18 (2.05)

0.035

− 1.06

(− 1.44, − 0.64)

− 1.51 (1.56)

 < 0.001

− 0.96

(− 1.18, − 0.76)

  1. MBSR = Mindfulness-based stress reduction. BEAT Cancer trial = Better Exercise Adherence after Treatment for Cancer trial. SRM = Standardized Response Mean. FSI = Fatigue Symptom Inventory
  2. “Worse” and “Better” are defined as ≥ 1 SEM decrease/increase from baseline to follow-up in the Short Form-36 Vitality subscale. Follow-ups for all trials occurred post-intervention (i.e., 2 months post-baseline for MBSR trials and 3 months post-baseline for the BEAT Cancer trial). P-values are from pairwise t-tests of change scores in the “Worse” or “Better” group compared with the change score in the “Same” group for each measure. Each SRM was calculated as the change score/SD of the change score. The 95% CIs for each SRM were calculated via bias-corrected bootstrapping with 10,000 samples using MedCalc software